AEON Biopharma shares surge 14.09% premarket after $22M fundraise and positive ABP-450 biosimilarity data submission to FDA.

AEON Biopharma surged 14.09% in premarket trading following two significant announcements. The company disclosed a $22 million capital-raising plan, including a $6 million private placement and a $15 million convertible note exchange with Daewoong, which will eliminate over 90% of its debt and extend cash runway to mid-2026. Additionally, AEON reported robust biosimilarity data for ABP-450, demonstrating 100% amino acid sequence identity with BOTOX® and strong functional assay results, ahead of its scheduled FDA Type 2a meeting. These developments strengthen AEON’s financial position, accelerate biosimilar program timelines, and enhance regulatory confidence, collectively driving the sharp premarket increase.